Canaccord raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $408 from $361 and keeps a Sell rating on the shares. The firm said they delivered its usual beat-and-raise, meaning it was basically an in-line quarter. Canaccord said they remain below consensus in the near- and medium-term given ongoing quarters around launch dynamics, in acute pain in particular.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $451 from $437 at RBC Capital
- Vertex Pharmaceuticals price target raised to $486 from $480 at Scotiabank
- Vertex Pharmaceuticals price target raised to $560 from $502 at Bernstein
- Vertex Pharmaceuticals price target raised to $476 from $473 at Morgan Stanley
- Vertex Pharmaceuticals Reports Strong Q3 2024 Growth